US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist
  • 1.310
  • -0.030-2.24%
Close Dec 20 16:00 ET
  • 1.306
  • -0.004-0.28%
Post 20:05 ET
108.14MMarket Cap-0.52P/E (TTM)

Editas Medicine Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-98.86%61K
-82.23%513K
-88.48%1.14M
296.32%78.12M
818.74%60.05M
12,604.76%5.34M
-54.62%2.89M
45.49%9.85M
-22.83%19.71M
-47.58%6.54M
Operating revenue
-98.86%61K
-82.23%513K
-88.48%1.14M
296.32%78.12M
818.74%60.05M
12,604.76%5.34M
-54.62%2.89M
45.49%9.85M
-22.83%19.71M
-47.58%6.54M
Cost of revenue
Gross profit
Operating expense
18.43%65.73M
54.14%72.42M
12.03%68.13M
0.67%247.3M
20.05%84.01M
-3.58%55.5M
-22.47%46.98M
5.72%60.81M
12.33%245.66M
29.41%69.98M
Selling and administrative expenses
20.69%18.09M
5.84%18.21M
-15.95%19.34M
-1.49%69.65M
-19.62%14.46M
-7.69%14.99M
1.56%17.2M
17.72%23.01M
-7.19%70.7M
8.82%17.98M
-General and administrative expense
20.69%18.09M
5.84%18.21M
-15.95%19.34M
-1.49%69.65M
-19.62%14.46M
-7.69%14.99M
1.56%17.2M
17.72%23.01M
-7.19%70.7M
8.82%17.98M
Research and development costs
17.59%47.64M
82.04%54.21M
29.05%48.79M
1.54%177.65M
33.77%69.56M
-1.97%40.51M
-31.79%29.78M
-0.45%37.8M
22.77%174.96M
38.47%52M
Operating profit
-30.91%-65.67M
-63.07%-71.9M
-31.46%-66.99M
25.12%-169.18M
62.23%-23.96M
12.79%-50.16M
18.70%-44.09M
-0.42%-50.96M
-16.98%-225.95M
-52.48%-63.45M
Net non-operating interest income expense
-31.38%3.53M
12.75%4.3M
43.49%5.04M
218.34%17.57M
88.13%5.1M
186.89%5.14M
597.99%3.81M
648.19%3.51M
809.06%5.52M
1,449.71%2.71M
Non-operating interest income
-31.38%3.53M
12.75%4.3M
43.49%5.04M
218.34%17.57M
88.13%5.1M
186.89%5.14M
597.99%3.81M
--3.51M
809.06%5.52M
1,449.71%2.71M
Other net income (expense)
-5K
85.71%-1K
100.38%6K
-1.6M
-14K
-102.98%-7K
-576.92%-1.58M
Other non- operating income (expenses)
---5K
85.71%-1K
100.38%6K
---1.6M
---14K
----
-102.98%-7K
-576.92%-1.58M
----
----
Income before tax
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
-14.51%-220.43M
-46.58%-60.74M
Income tax
Net income
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
-14.51%-220.43M
-46.58%-60.74M
Net income continuous Operations
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
-14.51%-220.43M
-46.58%-60.74M
Minority interest income
Net income attributable to the parent company
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
-14.51%-220.43M
-46.58%-60.74M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-38.03%-62.14M
-67.80%-67.61M
-26.34%-61.95M
30.49%-153.22M
68.93%-18.87M
19.21%-45.02M
24.63%-40.29M
2.93%-49.04M
-14.51%-220.43M
-46.58%-60.74M
Basic earnings per share
-36.36%-0.75
-46.43%-0.82
-7.04%-0.76
37.07%-2.02
73.86%-0.23
32.10%-0.55
28.21%-0.56
4.05%-0.71
-12.63%-3.21
-44.26%-0.88
Diluted earnings per share
-36.36%-0.75
-46.43%-0.82
-7.04%-0.76
37.07%-2.02
73.86%-0.23
32.10%-0.55
28.21%-0.56
4.05%-0.71
-12.63%-3.21
-44.26%-0.88
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue -98.86%61K-82.23%513K-88.48%1.14M296.32%78.12M818.74%60.05M12,604.76%5.34M-54.62%2.89M45.49%9.85M-22.83%19.71M-47.58%6.54M
Operating revenue -98.86%61K-82.23%513K-88.48%1.14M296.32%78.12M818.74%60.05M12,604.76%5.34M-54.62%2.89M45.49%9.85M-22.83%19.71M-47.58%6.54M
Cost of revenue
Gross profit
Operating expense 18.43%65.73M54.14%72.42M12.03%68.13M0.67%247.3M20.05%84.01M-3.58%55.5M-22.47%46.98M5.72%60.81M12.33%245.66M29.41%69.98M
Selling and administrative expenses 20.69%18.09M5.84%18.21M-15.95%19.34M-1.49%69.65M-19.62%14.46M-7.69%14.99M1.56%17.2M17.72%23.01M-7.19%70.7M8.82%17.98M
-General and administrative expense 20.69%18.09M5.84%18.21M-15.95%19.34M-1.49%69.65M-19.62%14.46M-7.69%14.99M1.56%17.2M17.72%23.01M-7.19%70.7M8.82%17.98M
Research and development costs 17.59%47.64M82.04%54.21M29.05%48.79M1.54%177.65M33.77%69.56M-1.97%40.51M-31.79%29.78M-0.45%37.8M22.77%174.96M38.47%52M
Operating profit -30.91%-65.67M-63.07%-71.9M-31.46%-66.99M25.12%-169.18M62.23%-23.96M12.79%-50.16M18.70%-44.09M-0.42%-50.96M-16.98%-225.95M-52.48%-63.45M
Net non-operating interest income expense -31.38%3.53M12.75%4.3M43.49%5.04M218.34%17.57M88.13%5.1M186.89%5.14M597.99%3.81M648.19%3.51M809.06%5.52M1,449.71%2.71M
Non-operating interest income -31.38%3.53M12.75%4.3M43.49%5.04M218.34%17.57M88.13%5.1M186.89%5.14M597.99%3.81M--3.51M809.06%5.52M1,449.71%2.71M
Other net income (expense) -5K85.71%-1K100.38%6K-1.6M-14K-102.98%-7K-576.92%-1.58M
Other non- operating income (expenses) ---5K85.71%-1K100.38%6K---1.6M---14K-----102.98%-7K-576.92%-1.58M--------
Income before tax -38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M-14.51%-220.43M-46.58%-60.74M
Income tax
Net income -38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M-14.51%-220.43M-46.58%-60.74M
Net income continuous Operations -38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M-14.51%-220.43M-46.58%-60.74M
Minority interest income
Net income attributable to the parent company -38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M-14.51%-220.43M-46.58%-60.74M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -38.03%-62.14M-67.80%-67.61M-26.34%-61.95M30.49%-153.22M68.93%-18.87M19.21%-45.02M24.63%-40.29M2.93%-49.04M-14.51%-220.43M-46.58%-60.74M
Basic earnings per share -36.36%-0.75-46.43%-0.82-7.04%-0.7637.07%-2.0273.86%-0.2332.10%-0.5528.21%-0.564.05%-0.71-12.63%-3.21-44.26%-0.88
Diluted earnings per share -36.36%-0.75-46.43%-0.82-7.04%-0.7637.07%-2.0273.86%-0.2332.10%-0.5528.21%-0.564.05%-0.71-12.63%-3.21-44.26%-0.88
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
MicroStrategy
MSTR
+11.56%
Adobe
ADBE
+2.24%
Salesforce
CRM
+2.21%
Apple
AAPL
+1.88%
Meritage Homes
MTH
+1.78%

Unlock the Full List

Investment Theme Gene Editing
Gene Editing
Intraday+0.52%